Results 221 to 230 of about 72,840 (299)

Plasma Metabolic Characteristics and Potential Biomarker Combinations in Schizophrenia Patients With Tardive Dyskinesia. [PDF]

Schizophr Bull
Lu C, Dong Y, Qi D, Liu N, Li Y, Chi J, Wang X, Zeng M, Liu F, Li S, Li J.   +10 more
europepmc   +1 more source

Is antipsychotic medication stigmatizing for people with mental illness? [PDF]

, 2009
Jenkins, Janis H, Sajatovic, Martha
core  

Phenotypic characteristics of paroxysmal dyskinesia in 25 cats

Journal of Small Animal Practice, EarlyView.
Objectives Paroxysmal dyskinesia has, to date, been reported only systematically in Sphynx cats. This study aims to describe paroxysmal dyskinesia in additional breeds. Materials and Methods The medical records of cats from multiple hospitals presenting with episodes consistent with paroxysmal dyskinesia between 2020 and 2025 were retrospectively ...
T. Liatis, C. Maeso, A. De Stefani, A. Pergande, T. Elvira, A. Suñol   +5 more
wiley   +1 more source

Wearable sensor measurements in relation to clinical characteristics and mortality in patients with Parkinson's disease. [PDF]

Neurol Res Pract
von Below D, Wallerstedt SM, Bergquist F.   +2 more
europepmc   +1 more source

The Diagnosis of Primary Ciliary Dyskinesia: Putting The European Respiratory/American Thoracic Guideline Into Practice. [PDF]

Pediatr Pulmonol
Harman K, Horani A, Shoemark A.
europepmc   +1 more source

Two Distinct Clinical Presentations of Primary Ciliary Dyskinesia (PCD): Diagnostic Utility of Whole-Exome Sequencing in a Genetically Heterogeneous Disorder. [PDF]

Appl Clin Genet
Górecki M, Jaszczuk I, Lejman M.
europepmc   +1 more source

Cilia Dynamics in Primary Ciliary Dyskinesia: A Biophysical Characterization of the <i>RSPH4A</i> Founder Variant. [PDF]

Cells
Rosario-Ortiz G, Muñiz-Hernández J, Ortiz-Pérez NM, Ramos-Benitez MJ, Mosquera RA, De Jesús-Rojas W.   +5 more
europepmc   +1 more source

Adverse outcomes between VMAT2 and anticholinergics in tardive dyskinesia: A target trial emulation

Psychiatry and Clinical Neurosciences, EarlyView.
Aim Vesicular monoamine transporter 2 (VMAT2) inhibitors have been approved for the treatment of tardive dyskinesia (TD), whereas anticholinergic agents are still widely used for this condition. This study aimed to compare the risk of major clinical adverse outcomes among patients with TD treated with VMAT2 inhibitors versus anticholinergic agents ...
Tien‐Wei Hsu, Chih‐Wei Hsu, Ping‐Tao Tseng, Yi‐Ya Fang, Chuo‐Yu Lee, Yu‐Hsuan Lin, Brendon Stubbs, Trevor Thompson, Andre F. Carvalho, Yu‐Chen Kao, Jen‐Ping Chen, Fu‐Chi Yang, Chia‐Kuang Tsai, Chih‐Sung Liang   +13 more
wiley   +1 more source

Delayed Neurological Deficits Caused by Epidural Leakage of Intravertebral Contents in a Patient With Osteoporotic Vertebral Fracture. [PDF]

Cureus
Mamoru F, Hiratsuka Y, Katayama M, Ohtake Y.   +3 more
europepmc   +1 more source

Clozapine for treatment‐resistant schizophrenia with epilepsy: A case report

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Clozapine (CLOZ) is often avoided in treatment‐resistant schizophrenia with comorbid epilepsy due to seizure risks. We report a successful case managed through a cautious CLOZ titration guided by multimodal monitoring, including clinical scales and blood tests such as C‐reactive protein (CRP), CLOZ levels, and anti‐seizure medication (ASM) levels ...
Toru Horinouchi, Mayusa Mito, Toshiyuki Ishikawa, Yuichi Nakamura, Shuhei Ishikawa, Naoki Hashimoto   +5 more
wiley   +1 more source